Compare DexCom, Inc. (DXCM) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Las Vegas Sands Corp. — how do they compare? DexCom, Inc. trades at $83.88 (market cap $31.86B), while Las Vegas Sands Corp. trades at $36.09 (market cap $23.38B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Las Vegas Sands Corp. pays a 3.32% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Las Vegas Sands Corp. for 72 Days on average.
| DXCM | LVS | |
|---|---|---|
Market Cap | $31.86B | $23.38B |
Volume | 3,607,070 | 6,994,661 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $69.49 |
52-Week Low | $54.84 | $35.81 |
Typical Hold Time | 62 Days | 72 Days |
Enterprise Value | $31.32B | $35.27B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
LVS trades at $36.15, up 0.95% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong revenue growth to $13.02B in 2025 and a net income of $1.63B, with a P/E of 13.99 suggesting reasonable valuation. Recent news highlights Sands China's community initiatives and awards, while Q2 2026 earnings missed expectations.
The investment outlook is mixed: analyst consensus is bullish with a $59.78 price target, but high debt levels and a recent earnings miss pose risks. Upside potential exists if the company maintains revenue growth and executes its stock repurchase program, though sensitivity to Macao's tourism recovery and interest rates remains a key concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
